US12529R1077

C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business HighlightsC4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

February 27, 2025 07:00 ET  | Source: C4 Therapeutics, Inc. Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical…

1 month ago
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 DegraderC4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

December 08, 2024 12:30 ET | Source: C4 Therapeutics, Inc. In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest…

4 months ago